Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma

The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases...

Full description

Bibliographic Details

Published in:	Frontiers in immunology Vol. 14; p. 1178060
Main Authors:	Teppert, Karin, Winter, Nora, Herbel, Vera, Brandes, Caroline, Lennartz, Simon, Engert, Fabian, Kaiser, Andrew, Schaser, Thomas, Lock, Dominik
Format:	Journal Article
Language:	English
Published:	Frontiers Media S.A 11.10.2023
Subjects:	adoptive T cell therapy chimeric antigen receptor chimeric costimulatory receptor Immunology immunotherapy melanoma
ISSN:	1664-3224, 1664-3224
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!